ACACA and Hepatic steatosis: Furthermore, MK-4074, another potent liver targeted inhibitor of ACC1/2, reduced DNL with both single doses and 7-day treatments in healthy subjects; it improved hepatic steatosis with 4 weeks of treatment [20].